Drug Identification System

PillID

Pill Identifier Drug Encyclopedia Drug Classes Compare Interactions Blog 🌙

Uses & FDA Indications

Olanzapine is a second-generation (atypical) antipsychotic approved by the FDA for the acute and maintenance treatment of schizophrenia in adults and adolescents (ages 13 and older), and for the treatment of acute manic or mixed episodes associated with bipolar I disorder — both as monotherapy and in combination with lithium or valproate. It is also FDA-approved as maintenance monotherapy for bipolar I disorder to prevent recurrence of mood episodes.

In combination with fluoxetine, olanzapine is marketed as Symbyax, which carries separate FDA approval for bipolar depression and treatment-resistant major depressive disorder — one of the few antipsychotic combination products with this specific indication.

Clinically established off-label uses include agitation management (particularly via intramuscular injection in acute psychiatric settings), adjunct antiemetic therapy in chemotherapy regimens (olanzapine has demonstrated effectiveness in preventing delayed chemotherapy-induced nausea and vomiting), and acute delirium management in inpatient settings. It is also occasionally used as an augmentation strategy in refractory major depression.

How It Works

Olanzapine belongs to the thienobenzodiazepine chemical class and exerts its effects through antagonism at multiple receptor types. Its primary antipsychotic action derives from blockade of dopamine D2 receptors in mesolimbic pathways, reducing positive symptoms of psychosis (hallucinations, delusions, disorganized thinking). Concurrent 5-HT2A serotonin receptor antagonism is thought to reduce D2 blockade in nigrostriatal pathways, which lowers the incidence of extrapyramidal side effects compared to first-generation antipsychotics.

Beyond D2 and 5-HT2A, olanzapine has high affinity for several additional receptor systems that directly shape its clinical profile: histamine H1 antagonism (producing potent sedation and contributing substantially to weight gain and appetite stimulation), muscarinic M1 receptor antagonism (anticholinergic effects: dry mouth, constipation, blurred vision, urinary retention), alpha-1 adrenergic antagonism (orthostatic hypotension, dizziness), and 5-HT2C antagonism (further contributing to weight gain and metabolic effects).

Side Effects

Common

• Weight gain — among the most significant concerns; substantial weight increases are common. Olanzapine is consistently ranked as one of the highest weight-gain antipsychotics in comparative studies.
• Sedation and somnolence — H1 antagonism produces pronounced sedation, particularly early in treatment. Can be therapeutically useful for agitation but functionally limiting for many patients.
• Dry mouth, constipation, blurred vision — anticholinergic effects from M1 blockade
• Orthostatic hypotension and dizziness — alpha-1 adrenergic blockade; greatest risk on initiation and dose increases
• Elevated blood glucose — hyperglycemia occurs independently of weight gain; mechanism involves direct pancreatic effects and insulin resistance
• Dyslipidemia — elevated triglycerides and LDL; reduced HDL
• Peripheral edema

Serious

• Metabolic syndrome — the combination of weight gain, hyperglycemia, dyslipidemia, and hypertension represents a major long-term risk, substantially increasing cardiovascular morbidity. Regular metabolic monitoring is essential.
• New-onset type 2 diabetes mellitus — olanzapine can precipitate or unmask diabetes, including in patients without obesity risk factors. Ketoacidosis has occurred rarely, including in non-obese patients.
• Tardive dyskinesia — involuntary repetitive movements resulting from chronic dopamine receptor blockade. Risk is lower than with first-generation antipsychotics but not negligible with long-term use.
• Neuroleptic malignant syndrome (NMS) — rare but potentially fatal: hyperthermia, muscle rigidity, altered consciousness, autonomic instability. Requires immediate discontinuation.
• Extrapyramidal symptoms (EPS) — akathisia, parkinsonism, dystonia. Less common than with typical antipsychotics but can occur, particularly at higher concentrations.
• Post-injection delirium/sedation syndrome (PDSS) — specific to the extended-release IM form (Zyprexa Relprevv); inadvertent intravascular injection can cause severe sedation and delirium. Requires 3-hour post-injection monitoring at a registered healthcare facility.
• Seizures — olanzapine lowers the seizure threshold; caution in patients with seizure disorders
• Hepatotoxicity — elevations in hepatic transaminases occur; rarely clinically significant

Drug Interactions

Drug / Class	Interaction	Clinical Significance
CNS Depressants (benzodiazepines, opioids, alcohol, sleep aids)	Additive CNS depression — excessive sedation, respiratory depression. Intravenous lorazepam combined with IM olanzapine has been associated with respiratory depression and cardiac arrest.	High — avoid concurrent parenteral use of IM olanzapine and parenteral benzodiazepines
Anticholinergic Drugs (TCAs, antihistamines, bladder agents, scopolamine)	Additive anticholinergic burden — dry mouth, constipation, urinary retention, tachycardia, cognitive impairment, delirium risk.	Moderate-High — monitor anticholinergic burden, particularly in elderly
Antihypertensives / Antidiabetics	Olanzapine's metabolic effects (hyperglycemia, weight gain, dyslipidemia) can antagonize antidiabetic drugs and complicate blood pressure management. Dose adjustments of concurrent medications may be required.	Moderate — monitor glucose, lipids, and blood pressure; adjust antidiabetic and antihypertensive therapy as needed
Fluvoxamine (Luvox)	Fluvoxamine inhibits CYP1A2, the primary enzyme responsible for olanzapine metabolism. Co-administration increases olanzapine plasma concentrations substantially, raising toxicity risk.	High — consider olanzapine dose reduction when adding fluvoxamine
Carbamazepine, Rifampin, Tobacco Smoke (CYP1A2 Inducers)	Induction of CYP1A2 and/or UGT1A4 accelerates olanzapine clearance, reducing plasma levels. Tobacco smokers may require higher doses; cessation can cause olanzapine toxicity at the same dose.	Moderate-High — adjust olanzapine based on smoking status and CYP1A2 inducer co-administration
Levodopa / Dopamine Agonists	Olanzapine's D2 antagonism counteracts the therapeutic effect of dopamine agonists used for Parkinson's disease.	Moderate — generally avoid in Parkinson's patients; consider quetiapine or clozapine if antipsychotic required
QT-Prolonging Drugs (other antipsychotics, fluoroquinolones, methadone, ondansetron)	Additive QTc prolongation. Olanzapine itself has modest QT-prolonging potential; risk increases with combination QT drugs.	Moderate — review QTc and electrolytes when combining multiple QT-prolonging agents

Warnings & Contraindications

Contraindications

• Known hypersensitivity to olanzapine
• Not approved and carries black box warning for dementia-related psychosis in elderly patients

Metabolic Monitoring

Given the substantial metabolic risks — weight gain, hyperglycemia, new-onset diabetes, and dyslipidemia — clinical guidelines recommend systematic monitoring at baseline and at regular intervals throughout treatment. Parameters to monitor include weight and BMI, waist circumference, fasting glucose or HbA1c, fasting lipid panel, and blood pressure. Clinicians should be prepared to initiate treatment for diabetes or dyslipidemia that emerges during olanzapine therapy, or to consider switching to a metabolically neutral antipsychotic when metabolic complications become significant.

Tardive Dyskinesia

Long-term dopamine D2 receptor blockade can result in tardive dyskinesia — involuntary, repetitive movements of the face, tongue, lips, and extremities that may become irreversible. Risk increases with duration of treatment and cumulative exposure. If signs of tardive dyskinesia emerge, dose reduction or discontinuation should be evaluated. Valbenazine (Ingrezza) and deutetrabenazine (Austedo) are FDA-approved to treat tardive dyskinesia if discontinuation is not feasible.

Neuroleptic Malignant Syndrome

NMS is a rare, potentially fatal reaction to antipsychotic medications characterized by hyperthermia, severe muscle rigidity, altered mental status, and autonomic dysfunction (diaphoresis, tachycardia, blood pressure instability). If NMS is suspected, olanzapine must be discontinued immediately and intensive supportive care initiated. The syndrome can occur at any point during treatment, including at stable doses.

Pregnancy and Lactation

Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk for extrapyramidal symptoms and withdrawal symptoms after delivery — agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding difficulty. Olanzapine is excreted in breast milk; breastfeeding decisions should balance maternal need against infant risk with individualized clinical guidance.

Frequently Asked Questions

Does olanzapine cause weight gain?

Yes — olanzapine is one of the antipsychotics most strongly associated with weight gain. Weight increases of 10 pounds or more are common, and gains exceeding 20–30 pounds occur in a significant subset of patients, particularly during the first several months of treatment. The mechanism involves H1 receptor antagonism (increasing appetite and sedation), antagonism of 5-HT2C receptors, and possible effects on leptin and insulin signaling. Metabolic monitoring — weight, waist circumference, fasting glucose, and lipid panels — is recommended regularly during treatment.

What is the difference between olanzapine and typical antipsychotics?

Olanzapine is a second-generation (atypical) antipsychotic, distinguished from first-generation (typical) agents like haloperidol primarily by its broader receptor binding profile. It blocks both dopamine D2 receptors and serotonin 5-HT2A receptors, which is thought to reduce the risk of extrapyramidal side effects (movement disorders) compared to drugs that primarily block D2 alone. However, atypical antipsychotics including olanzapine carry greater metabolic risks — weight gain, dyslipidemia, and type 2 diabetes — that are less pronounced with many typical agents.

Is olanzapine used for conditions other than schizophrenia?

Yes. Beyond its primary FDA-approved indications for schizophrenia and bipolar disorder (manic and mixed episodes, as well as maintenance), olanzapine has several established off-label uses. These include treatment-resistant depression when combined with fluoxetine (sold as Symbyax), agitation management in emergency settings, nausea and vomiting associated with chemotherapy (particularly in combination antiemetic regimens), and delirium management in some inpatient settings. The olanzapine/fluoxetine combination (Symbyax) is also FDA-approved for treatment-resistant depression and bipolar depression.

→ Antipsychotic Side Effects Guide